IDEAYA Biosciences, Inc. $IDYA Holdings Lifted by Sei Investments Co.

Sei Investments Co. boosted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 23.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,760 shares of the company’s stock after buying an additional 16,053 shares during the period. Sei Investments Co. owned approximately 0.10% of IDEAYA Biosciences worth $2,825,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. GSK plc purchased a new position in IDEAYA Biosciences during the 4th quarter valued at about $46,093,000. State Street Corp lifted its position in shares of IDEAYA Biosciences by 27.6% in the fourth quarter. State Street Corp now owns 4,134,641 shares of the company’s stock worth $142,935,000 after purchasing an additional 893,707 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of IDEAYA Biosciences by 11.8% in the fourth quarter. Janus Henderson Group PLC now owns 7,186,456 shares of the company’s stock worth $248,344,000 after purchasing an additional 758,117 shares in the last quarter. First Turn Management LLC acquired a new stake in shares of IDEAYA Biosciences during the fourth quarter worth approximately $25,017,000. Finally, Fiera Capital Corp boosted its holdings in shares of IDEAYA Biosciences by 32.6% during the fourth quarter. Fiera Capital Corp now owns 2,437,262 shares of the company’s stock worth $84,256,000 after purchasing an additional 599,295 shares during the period. 98.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at IDEAYA Biosciences

In related news, CAO Briseno Andres Ruiz sold 9,550 shares of IDEAYA Biosciences stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total value of $382,095.50. Following the completion of the sale, the chief accounting officer owned 26,466 shares of the company’s stock, valued at approximately $1,058,904.66. The trade was a 26.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Stock Performance

NASDAQ:IDYA opened at $37.02 on Friday. The company has a market capitalization of $3.25 billion, a P/E ratio of -19.08 and a beta of -0.10. The stock’s 50 day moving average price is $34.38 and its 200 day moving average price is $32.68. IDEAYA Biosciences, Inc. has a 52 week low of $22.22 and a 52 week high of $40.58.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Tuesday, August 4th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). The business had revenue of $8.86 million during the quarter, compared to analyst estimates of $8.02 million. IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. IDEAYA Biosciences’s revenue was up 8800.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.88) earnings per share. As a group, sell-side analysts forecast that IDEAYA Biosciences, Inc. will post -4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Citigroup reiterated a “market outperform” rating on shares of IDEAYA Biosciences in a research note on Tuesday, June 2nd. The Goldman Sachs Group lifted their target price on shares of IDEAYA Biosciences from $31.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, April 14th. Wells Fargo & Company boosted their price target on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, April 14th. Wedbush upped their price target on shares of IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Mizuho cut their price objective on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.12.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.